Table 3 Summary of findings with potential to indicate mechanisms underlying clinical efficacy in alemtuzumab-treated patients

% regulatory T cells (Treg: CD4+CD25^hiCD127^lo/neg foxP3+)

Sustained increase from M5 through M23 (Fig. 1)

% effector T cells (Teff: CD4+CD25+CD127+foxP3-)

No change from M0 (Fig. 1)

Ratio of Teff:Treg in PBMC

Sustained reduction from M0 through M23 (Fig. 1)

Regulatory T cell function

Increased at M5 and M17 (Fig. 1)

% memory B cells (CD19+CD27+)

Sustained reduction from M5 through M36 (Fig. 3)

% naïve “regulatory” B cells (CD19+CD20+CD27-CD24^hiCD38^hi)

Sustained increase from M5 through M23 (Fig. 3)

Ratio of memory B cells:naïve “regulatory” B cells

Sustained reduction from M5 through M23 (Fig. 3)

% NK cells (CD3-CD56+)

Sustained increase from M5 through M23 (Fig. 4)

% "regulatory" NK cells (CD3-CD56^bright)

Sustained increase from M5 through M36 (Fig. 4)

Ratio of NKT cells:CD3-CD56^bright

Sustained reduction from M5 through M36 (Fig. 4)

IL-2 (pg/mL)

Sustained reduction from M5 through M23 (Fig. S4)

IFN-γ (pg/mL)

Sustained reduction from M5 through M23 (Fig. S4)

IL-17A (pg/mL)

Sustained reduction at M5, M11 and M23 (Fig. S4)

IL-10 (pg/mL)

No change from M0 (Fig. S4)